Establishing New Core Products in the Healthcare Field
First written in FY2019. 18 of 21 entries say "Advanced", first in FY2020. Latest entry: 2026-08-07.
8 other companies' latest entry also says "Advanced".
- 2026-08-07AdvancedFinancial results briefing materials
「Healthcare business Fun and Health expected to achieve its ¥10 billion medium-term plan target one year ahead of schedule」
The company expects to achieve the healthcare sales target under its medium-term management plan one year ahead of schedule, driven by sales growth at Fun and Health. - FY2026-H1AdvancedAnnual report
「The launch of the new Slimore Coffee Latte expanded the customer base and is further accelerating brand growth. Going forward, we will continue to drive new-customer acquisition by expanding the series and increasing customers’ choices.」
Fun and Health launched Slimore Coffee Latte and is pursuing new-customer acquisition by expanding its customer base and the product series. - FY2025AdvancedAnnual report
「In healthcare’s Fun and Health business, stable growth in the flagship functional food W no Kenko Aojiru, together with continued strong new-customer acquisition for Slimore Coffee, resulted in substantial sales growth for the brand and drove company-wide growth.」
Stable growth in W no Kenko Aojiru and continued new-customer acquisition for Slimore Coffee resulted in substantial sales growth for the Fun and Health brand and drove company-wide growth. - FY2025-H1AdvancedAnnual report
「In healthcare’s Fun and Health business, a strong retention rate for subscriptions to the flagship functional food W no Kenko Aojiru established a revenue base for the brand, while continued strong new-customer acquisition for Slimore Coffee resulted in substantial sales growth.」
W no Kenko Aojiru established a revenue base for the brand on the back of a high subscription retention rate. Strong new-customer acquisition for Slimore Coffee continued, resulting in substantial sales growth. - FY2024AdvancedAnnual report
「The new product Slimore Coffee, launched in March, performed well in test sales and moved into a phase of increased marketing investment to develop it into a new core product.」
The company launched Slimore Coffee in the healthcare field and, following strong test sales, moved into a phase of increased marketing investment to develop it into a new core product. W no Kenko Aojiru and Wellness Food also continued to grow. - FY2024-Q2AdvancedAnnual report
「In healthcare’s Fun and Health business, strong sales of the flagship functional food W no Kenko Aojiru continued, and EC sales of Wellness Food grew steadily.」
Strong sales of W no Kenko Aojiru continued, and Wellness Food’s EC sales grew steadily. - FY2024-Q1AdvancedAnnual report
「In healthcare, sales continued to expand as ongoing digital advertising investment in the functional food W no Kenko Aojiru generated new-customer acquisition and existing customers maintained a high repeat-purchase rate.」
The company continued digital advertising investment in W no Kenko Aojiru, acquiring new customers, while sales expanded on the back of a high repeat-purchase rate among existing customers. - FY2023AdvancedAnnual report
「To grow healthcare into the company’s second core business after cosmetics, we recognize that, in addition to expanding the existing healthcare business, developing and nurturing new healthcare businesses is an important challenge. Specifically, we will strengthen initiatives including the continued launch of highly functional new products, the development of hit products by leveraging our direct-sales capabilities, and customer development through stronger cross-selling to cosmetics customers.」
The company reaffirmed its policy of growing healthcare into its second core business after cosmetics and identified the continued launch of highly functional new products, development of hit products and cross-selling to cosmetics customers as specific measures. - FY2023-Q3AdvancedAnnual report
「In healthcare, improved advertising efficiency for the functional food W no Kenko Aojiru led to further growth in new-customer acquisition through EC, driving sales growth.」
Advertising efficiency for W no Kenko Aojiru improved, and further growth in new-customer acquisition through EC drove sales growth. - FY2023-Q2AdvancedAnnual report
「In healthcare, differentiation by targeting specific needs such as high blood pressure and body fat for the functional food W no Kenko Aojiru proved effective. Strong new-customer acquisition enabled the company to steadily expand its share and drive sales even in the stable domestic market.」
For W no Kenko Aojiru, differentiation by targeting specific needs such as high blood pressure and body fat attracted new customers and expanded market share in Japan. - FY2023-Q1RestatedAnnual report
「In healthcare, increased advertising investment in the functional food W no Kenko Aojiru, continuing from the previous consolidated fiscal year, resulted in strong new-customer acquisition.」
The company strengthened advertising investment in W no Kenko Aojiru for the second consecutive consolidated fiscal year, and new-customer acquisition remained strong. - FY2022-Q3AdvancedAnnual report
「In health foods, increased advertising investment in the functional food W no Kenko Aojiru resulted in strong new-customer acquisition.」
The company increased advertising investment in W no Kenko Aojiru, a healthcare product, and new-customer acquisition remained strong. - FY2022-Q2AdvancedAnnual report
「The number of stores carrying growth brands such as the PERFECT ONE FOCUS skincare brand for younger customers and the BODY AURA healthcare brand for customers in their 30s and 40s expanded steadily.」
The number of stores carrying BODY AURA, a growth brand in the healthcare field, continued to increase. - FY2022-Q1AdvancedAnnual report
「Drugstore rollout and promotional activities for the newly launched BODY AURA BOOSTER drink and BODY AURA ENERGY tablet progressed smoothly, expanding points of contact with new customer segments.」
The company launched 2 new BODY AURA products in the healthcare field and advanced their drugstore rollout and promotional activities. - FY2021RaisedAnnual report
「To grow healthcare into the company’s second core business after cosmetics, we recognize that, in addition to expanding the existing healthcare business, developing and nurturing new healthcare businesses is an important challenge. We will actively pursue the development and nurturing of new healthcare businesses by expanding marketing investment, driving customer acquisition through stronger cross-selling, nurturing the Smart Healthcare business targeting working-age customers, and launching the Wellness Food business centered on MCT oil.」
The company clearly stated its policy of growing healthcare into its second core business after cosmetics and expanded the scope of its initiatives to Smart Healthcare, cross-selling and Wellness Food. - FY2021-Q2AdvancedAnnual report
「In the Smart Healthcare business, we launched BODY AURA, a supplement designed to support the ability to protect oneself, or self-defense, which is necessary for managing health in the new normal, and began selling it through our online shop and drugstores nationwide. Going forward, we will work to increase brand awareness and sales through TV commercials and social media.」
The company launched BODY AURA in the Smart Healthcare business and began selling it through its online shop and drugstores nationwide. It also outlined plans to increase awareness and sales through TV commercials and social media. - FY2021-Q1AdvancedAnnual report
「We newly launched the Smart Healthcare business in the first quarter of the current fiscal year and released Bikatsu Protein in October as its first product, designed to help build a strong and beautiful body. As “self-defense,” or managing one’s own health, attracts attention following the COVID-19 pandemic, the Smart Healthcare business plans to successively roll out products and services based on the concepts of “Evidence” (reliable, doctor-supervised product quality), “Lifestyle” (self-directed, smart values and behavior), and “SmartTech” (making the body and effects visible).」
The company newly launched the Smart Healthcare business and released Bikatsu Protein as its first product in October. It plans to develop products and services based on the concepts of Evidence, Lifestyle and SmartTech. - FY2020AdvancedAnnual report
「We launched the Smart Healthcare business and aim to expand our healthcare operations by providing new products and services that support people’s self-directed healthcare. Beginning with Bikatsu Protein, launched in October 2020, we plan to roll out a succession of new services and products that address beauty and health from both inside and outside the body.」
To create new healthcare staples and services, the company launched the Smart Healthcare business and progressed to the launch of Bikatsu Protein. - FY2019First statedAnnual report
「To establish new standards in healthcare, we are developing products that people will consider indispensable 10 years from now, and are also advancing the development of more distinctive and specialized products in new categories and service areas so that we can shape customers’ lifestyles.」
In healthcare, including health foods and pharmaceuticals, the company aims to develop products in new categories and services with a 10-year outlook.